首页 > 市场调查报告书 > 製药

糖尿病神经疾病

糖尿病神经病变市场规模、份额和成长分析（按疾病类型、药物类别、通路和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1899711

糖尿病神经病变市场规模、份额和成长分析（按疾病类型、药物类别、通路和地区划分）－2026-2033年产业预测

Diabetic Neuropathy Market Size, Share, and Growth Analysis, By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy), By Drug Class (Capsaicin, Opioid), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，糖尿病神经病变市场规模将达到 41.4409 亿美元，到 2025 年将达到 44.3003 亿美元，到 2033 年将达到 75.5489 亿美元，预测期（2026-2033 年）的复合年增长率为 6.9%。

糖尿病神经病变是一种以长期高血糖引起的神经损伤为特征的疾病，对糖尿病患者，尤其是长期糖尿病患者而言，构成重大挑战。虽然初期症状可能不明显，但随着时间的推移，神经损伤的风险会逐渐增加。遗憾的是，目前尚无治癒方法，但已建立了多种治疗方法来控制和预防疾病。由于该疾病的复杂性，任何新产品或治疗方案都必须受到监管。鑑于糖尿病神经病变的高发生率，尤其是在糖尿病患者中，医疗保健市场正在涌现出巨大的成长机会。随着人们对该疾病的认识不断提高，以及对有效管理措施的需求不断增长，预计糖尿病神经病变管理领域的市场发展和创新将会不断涌现。

糖尿病神经病变市场驱动因素

糖尿病神经病变市场受到糖尿病盛行率不断上升的显着影响，这推动了对有效治疗方法和管理方案的需求。此外，肥胖、冠状动脉心臟病和其他糖尿病相关併发症盛行率的上升也促进了市场成长。都市化也发挥关键作用，促使人们养成久坐不动的生活方式，其特征是高碳水化合物摄取和体力活动减少。这些相互关联的健康挑战不仅凸显了对更好治疗方法的需求，也为糖尿病神经病变市场的扩张创造了有利环境，因为医疗保健系统正努力满足受影响人群的需求。

限製糖尿病神经病变市场的因素

糖尿病神经病变市场面临诸多限制因素，阻碍其成长。治疗药物成本不断上涨，以及替代疗法的兴起，都加剧了市场挑战。其他治疗方案，例如放射线治疗和物理疗法，因其舒适性和有效性更高，可能促使消费者更倾向于选择这些替代疗法而非传统药物。此外，严格的监管准则、潜在的产品召回、监管核准流程的延误以及其他相关复杂因素，都构成了市场准入和扩张的壁垒，进一步限制了市场发展。

糖尿病神经病变市场趋势

随着创新技术和新型治疗方案的蓬勃发展，糖尿病神经病变市场正经历剧烈的变革。各公司积极探索先进的产品研发，例如经皮贴片、漱口水和特殊外用製剂，以提高治疗效果。先进给药系统的引入，包括无针注射器，正在解决药物给药的现有难题，并进一步激发人们对该领域的关注。这种创新驱动力，加上对替代给药途径（从口服和经皮到肠外和吸入）日益增长的需求，正在推动市场扩张，并改变糖尿病神经病变的治疗模式。

辣椒素
阿片类药物
- 氢可酮
- 其他的
非类固醇消炎剂（NSAIDs）
- Ibuprofen
- 萘普生
抗忧郁症
- 三环抗忧郁药物（TCAs）
- 阿米替林
- 丙咪嗪
- 正肾上腺素再回收抑制剂（SNRIs）
- Duloxetine
- 选择性血清素再回收抑制剂（SSRIs）
- 西酞普兰
- 帕罗西汀
- 抗惊厥药
- Gabapentin
- Pregabalin
- 托吡酯
其他的

全球糖尿病神经病变市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

医院药房
零售药房

全球糖尿病神经病变市场规模及复合年增长率（2026-2033）

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2021-2023年营收年比比较

主要企业简介

Abbott Laboratories
Eli Lilly and Company
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Lupin Pharmaceuticals, Inc.
Astellas Pharma US, Inc.
Bayer AG
Teva Pharmaceutical Industries Ltd.
NeuroMetrix Inc.
Helixmith Co., Ltd.
Johnson & Johnson Services, Inc.
Daiichi Sankyo Company, Limited
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics, Inc.
Alfasigma USA, Inc.
ExeGi Pharma LLC

结论与建议

简介目录

Product Code: SQMIG35I2245

Diabetic Neuropathy Market size was valued at USD 4144.09 Million in 2024 and is poised to grow from USD 4430.03 Million in 2025 to USD 7554.89 Million by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

Diabetic neuropathy, a nerve-damaging condition linked to prolonged hyperglycemia, poses significant challenges for patients, particularly those with long-standing diabetes. While early symptoms may be subtle, the risk of widespread nerve damage increases over time. Unfortunately, there is currently no cure; however, management and prevention techniques are available through various therapeutic approaches. The complexity of this condition necessitates regulatory oversight for new products and treatment options. This creates substantial growth opportunities for companies in the healthcare market, given the high prevalence of diabetic neuropathy predominantly among individuals with diabetes. As awareness of the condition increases and the demand for effective management options expands, businesses can expect to see significant market advancements and innovations in tackling diabetic neuropathy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetic Neuropathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Diabetic Neuropathy Market Segments Analysis

Global Diabetic Neuropathy Market is segmented by disorder type, drug class, distribution channel and region. Based on disorder type, the market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy and focal neuropathy. Based on drug class, the market is segmented into capsaicin, opioid, non-steroidal anti-inflammatory drugs (NSAIDS), antidepressants and other. Based on distribution channel, the market is segmented into hospitals pharmacies and retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Diabetic Neuropathy Market

The diabetic neuropathy market is significantly influenced by the increasing incidence of diabetes, which is driving demand for effective treatments and management solutions. Additionally, the rising prevalence of obesity, coronary heart disease, and other complications related to diabetes contribute to market growth. Urbanization also plays a critical role, as it encourages sedentary lifestyles characterized by high carbohydrate intake and reduced physical activity levels. These interconnected health challenges not only highlight the urgency for better therapeutic options but also foster an environment conducive to the expansion of the diabetic neuropathy market as healthcare systems strive to address the needs of affected populations.

Restraints in the Diabetic Neuropathy Market

The Diabetic Neuropathy market faces several constraints that hinder its growth. Increasing medication costs for treating this condition, along with the rise of alternative therapies, contribute to the challenges within the market. The availability of other treatment options, such as radiotherapy and physiotherapy, often perceived as more comfortable and effective, may lead consumers to prefer these alternatives over traditional medications. Additionally, the market's development is further restricted by strict regulatory guidelines, potential product recalls, delays in the approval process from authorities, and other related complications that create barriers to entry and expansion.

Market Trends of the Diabetic Neuropathy Market

The diabetic neuropathy market is witnessing a dynamic shift as innovative technologies and novel therapeutic solutions gain momentum. Companies are actively exploring the development of advanced products like transdermal patches, mouthwashes, and specialized topical solutions to enhance treatment efficacy. The introduction of sophisticated medication delivery systems, including syringe-free injection devices, addresses existing challenges in pharmaceutical administration, further propelling interest in this sector. This drive for innovation, combined with a growing demand for alternative drug delivery methods-ranging from oral and transdermal to parenteral and inhalation routes-is fueling market expansion and transforming the landscape of diabetic neuropathy management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies

Global Diabetic Neuropathy Market Size by Disorder Type & CAGR (2026-2033)

Market Overview
Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy

Global Diabetic Neuropathy Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Capsaicin
Opioid
- Morphine
- Others
Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
- Ibuprofen
- Naproxen
Antidepressants
- Tricyclic Antidepressants (Tcas)
- Amitriptyline
- Imipramine
- Serotonin And Norepinephrine Reuptake Inhibitors (Snris)
- Duloxetine
- Selective Serotonin Reuptake Inhibitors (Ssris)
- Citalopram
- Paroxetine
- Anticonvulsant Drugs
- Gabapentin
- Pregabalin
- Topiramate
Other

Global Diabetic Neuropathy Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospitals Pharmacies
Retail Pharmacies

Global Diabetic Neuropathy Market Size & CAGR (2026-2033)

North America (Disorder Type, Drug Class, Distribution Channel)
- USA
- Canada
Europe (Disorder Type, Drug Class, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disorder Type, Drug Class, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disorder Type, Drug Class, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Disorder Type, Drug Class, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma US, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeuroMetrix Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Helixmith Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akcea Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alfasigma USA, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ExeGi Pharma LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments